Clinical Trials

Learn More About Seraph 100 in Use

PURIFY Program

Initiated at Uniformed Services University of the Health Sciences (USUHS), the program is an off-shoot of the DARPA dialysis-like therapy (DLT) program aimed at developing and/or evaluating adjunctive therapies in a pandemic setting when no proven therapies are available. Seraph 100 is being tested in the ongoing PURIFY Program.

For additional details about the study, visit: https://deployedmedicine.com/market/215/content/1676

US IDE Multicenter Prospective Randomized Controlled Trial: PURIFY-RCT

Multi-center, randomized controlled trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated shock. Patients will be randomized to receive either Arm 1: Seraph 100 treatment plus ‘State of the Art’ or Arm 2: ‘State of the Art’ care alone. “State of the Art care” will be defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock.

For additional details about the study, visit: https://www.clinicaltrials.gov/ct2/show/NCT05011656

European Registry for Hemadsorption in Sepsis

Prospective, multicenter, observational registry of sepsis patients treated with the Seraph 100 Microbind Affinity Blood Filter to investigate possible advantages of early targeted treatment and to set indications/inclusion criteria for the treatment of ICU septic patients with the method of hemoadsorption.

For additional details about the study, visit: https://clinicaltrials.gov/study/NCT05608096

PURIFY OBS (completed)

Multi-center, observational 3-arm cohort study composed of subjects with informed consent (1) treated with Seraph 100 after the date of the EUA approval (retrospective), (2) additional eligible admitted patients also meeting inclusion/exclusion criteria (prospective), and (3) Historical matched control group composed of admitted patients at participating sites with severe COVID-19 infection, meeting EUA treatment criteria, but not treated with Seraph 100 (matched control).

For additional details about the study, visit: https://clinicaltrials.gov/ct2/show/NCT04606498

European COVID-19 Registry

Registry of COVID-19 patients treated with the Seraph 100 Microbind Affinity Blood Filter (COSA) with the purpose to investigate the effectiveness and safety of the Seraph 100 in the treatment of COVID-19 patients.

For additional details about the study, visit: https://clinicaltrials.gov/ct2/show/NCT04361500

Seraph 100 CE Mark Clinical Trial (completed)

ExThera Medical completed a multi-center, non-randomized European trial for Seraph 100 in 2019. The study enrolled patients at four centers in Germany.

For additional details about the study, visit: https://clinicaltrials.gov/show/NCT02914132

Learn More

MM0003 Rev A